OS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy

Reuters

06/10

<a href="https://laohu8.com/S/OSTX">OS Therapies</a> Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy

OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG06480) on June 10, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2542425319"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2542425319\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2542425319?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-10 19:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2542425319","market":"us","top_or_hot":-1,"title":"OS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG06480) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>OS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-10 19:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/OSTX\">OS Therapies</a> Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG06480) on June 10, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250610:nNDL2QlL18:1","article_id":"2542425319","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2542425319","pubTimestamp":1749555643,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. pub","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","OSTX":"OS Therapies"},"translate_title":"OS Therapies Inc.与EVERSANA合作在美国实现儿童骨肉瘤免疫疗法的商业化","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OSTX":0.9},"content_text":"OS Therapies Inc. Partners with EVERSANA for U.S. Commercialization of Pediatric Osteosarcoma Immunotherapy\n    \n\n        OS Therapies Inc., a clinical-stage cancer immunotherapy company, has announced a partnership with EVERSANA for the U.S. commercialization of OST-HER2, a novel immunotherapy designed for recurrent, fully resected, pediatric lung metastatic osteosarcoma. This collaboration will leverage EVERSANA's extensive experience in the life sciences industry to ensure efficient market access and patient services for OST-HER2. With this partnership, OS Therapies aims to transform the treatment landscape for pediatric metastatic osteosarcoma, utilizing EVERSANA's integrated commercialization model to bring the innovation swiftly and effectively to healthcare providers and patients.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: CG06480) on June 10, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}